Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · PTC Therapeutics (PTCT)

PTC Therapeutics closes $550 million convertible notes offering due 2031

Neutral Impact 3 of 5 financing Written later

PTC Therapeutics completed a private offering of $550 million in 0.0% convertible senior notes due June 15, 2031, including the full $50 million option exercised by the initial purchasers. The company is using about $328.8 million of the estimated $535.5 million net proceeds to repurchase $222.0 million of its existing 1.50% convertible notes due 2026, leaving $55.5 million of those notes outstanding, which shifts its debt toward the new notes for shareholders.

Key points

  • Notes: $550 million principal, 0.0% interest, maturing June 15, 2031
  • Initial conversion price of approximately $107.48 per share (9.3042 shares per $1,000 principal)
  • Estimated net proceeds of $535.5 million; $328.8 million used to repurchase $222.0 million of 2026 notes
  • Existing 1.50% convertible notes outstanding after repurchases: $55.5 million

The filing

CompanyPTC Therapeutics (PTCT)
Form8-K, current report
Filed with the SECJun 18, 2026, 4:14 PM ET
Accession number0001104659-26-075731

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation3.02 Unregistered Equity Sale8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:05 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 18, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.